<DOC>
	<DOCNO>NCT01109654</DOCNO>
	<brief_summary>This multicentric , prospective , observational study use Cetrotide control endogenous gonadotrophin level Gonal-f stimulate ART treatment cycle Asia-Pacific region . The study plan enrol approximately 1800-2000 subject 9-month period participate centre . This observational study initiate collect information use Cetrotide ( GnRH antagonist ) ART cycle routine practice across Asia-Pacific region . The information allow good understanding current ovarian stimulation regimen involve Cetrotide control endogenous gonadotrophin concentration . The collection live birth data , though challenging task , secondary endpoint allow study show valuable information final objective ART . To minimize potential variability due different ovarian stimulation agent , study include cycle treat Gonal-f ( recombinant human FSH ) since agent widely available region .</brief_summary>
	<brief_title>An Observational Study Cetrotide® Gonadotropin-releasing Hormone Antagonist ( GnRH Antagonist ) With GONAL-f® Assisted Reproductive Technologies ( ART )</brief_title>
	<detailed_description>Gonadotrophin-releasing hormone ( GnRH ) antagonists introduced begin decade use ART . The potential advantage GnRH antagonists GnRH agonist include avoidance acute stimulation endogenous gonadotrophin dramatic reduction length analogue treatment . Despite plus point GnRH antagonist ART , concern low pregnancy rate report , may cause low acceptance GnRH antagonists ovarian stimulation vitro fertilization ( IVF ) . Interestingly , separate meta-analysis reach finding . The probability live birth ovarian stimulation IVF find dependent type analogue use pituitary suppression Cetrotide , GnRH antagonist Merck Serono , currently approve inhibition premature luteinizing hormone ( LH ) surge woman undergo controlled ovarian stimulation majority region . It give either single-dose regimen 3 mg injection multiple-dose regimen 0.25 mg daily injection . Both regimen show offer equivalent efficacy safety outcomes . OBJECTIVES : Primary objective : - To assess effectiveness Cetrotide regimen , use Gonal-f , routine ART treatment cycle Secondary objective : - To assess effectiveness Cetrotide regimens efficacy endpoint - To survey type Cetrotide regimen use success rate - To assess safety Cetrotide regimens - To explore association subject characteristic treatment outcome</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormone Antagonists</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Subjects undergo ovarian stimulation IVF ICSI therapy Decision treat physician prescribe Gonalf control ovarian stimulation prior study enrolment Decision treat physician prescribe Cetrotide downregulation agent prior study enrolment Subjects use GnRH agonist downregulation agent Contraindicated use Cetrotide base local label Subjects participate study previously Subjects hypersensitivity cetrorelix acetate , extrinsic peptide hormone mannitol Subjects know hypersensitivity GnRH GnRH analogs Subjects know suspected pregnancy , lactation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Fertilization Vitro</keyword>
	<keyword>Reproductive Techniques , Assisted</keyword>
	<keyword>Follicle Stimulating Hormone</keyword>
	<keyword>Cetrotide</keyword>
	<keyword>Gonal-f</keyword>
</DOC>